Northwestern Mutual Wealth Management Co. Acquires New Shares in Boston Scientific Corporation $BSX

Northwestern Mutual Wealth Management Co. bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 839,483 shares of the medical equipment provider’s stock, valued at approximately $35,829,000. Northwestern Mutual Wealth Management Co. owned 0.06% of Boston Scientific as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Boston Scientific by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after purchasing an additional 1,436,550 shares during the last quarter. BlackRock Inc. acquired a new position in Boston Scientific during the second quarter worth approximately $5,534,781,000. State Street Corp raised its stake in Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after acquiring an additional 920,495 shares during the period. Capital World Investors lifted its stake in shares of Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after buying an additional 502,627 shares during the last quarter. Finally, Norges Bank acquired a new stake in Boston Scientific during the fourth quarter worth approximately $2,199,395,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Up 2.1%

NYSE:BSX opened at $50.39 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The firm’s fifty day moving average is $46.34 and its 200-day moving average is $57.86. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The firm has a market cap of $73.03 billion, a P/E ratio of 20.40, a P/E/G ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm’s revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Insider Activity

In related news, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of several recent research reports. Argus reiterated a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Leerink Partners set a $60.00 target price on Boston Scientific in a report on Thursday, July 30th. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Canaccord Genuity Group decreased their target price on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.